Brief: Cabaletta Bio Announces FDA Granted Orphan Drug Designation To CABA-201 For Treatment Of Myositis
01/02/2024 22:30
Feb 1 (Reuters) - Cabaletta Bio Inc CABA.O :
* CABALETTA BIO ANNOUNCES FDA GRANTED ORPHAN DRUG
DESIGNATION TO
CABA-201 FOR TREATMENT OF MYOSITIS
Source text for Eikon: ID:nGNX4GjffH
Further company coverage: CABA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cabaletta Bio
See all newsBrief: Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Cabaletta Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Cabaletta Bio Q2 net loss widens as R&D costs rise
Cabaletta Bio, Inc. expected to post a loss of 37 cents a share - Earnings Preview
Cabaletta Bio Inc expected to post a loss of 37 cents a share - Earnings Preview